Business
Collaboration agreement with ISA Pharmaceuticals
Collaboration agreement with ISA Pharmaceuticals.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 9322E Scancell Holdings Plc 15 February 2018 \n\n \nISA Pharmaceuticals and Scancell enter collaboration agreement for the manufacturing, development and commercialisation of Modi-1 / AMPLIVANT® combination\n \nAMPLIVANT-Modi-1 conjugate expected to enter clinic in H1 2019\nCollaboration seeks to further leverage Moditope® platform\n \nLeiden, The Netherlands, and Oxford, UK, 15 February, 2018 -- ISA Pharmaceuticals B.V. ('ISA'), a clinical-stage immunotherapy company, and Scancell Holdings plc, ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, are pleased to announce that they have entered into a worldwide licensing and collaboration agreement to use ISA's AMPLIVANT® adjuvant technology for the manufacturing, development and commercialisation of Scancell's first Moditope® development candidate, Modi-1. This partnership has the potential to provide a new treatment option for patients with triple negative breast cancer, ovarian cancer, sarcomas, and other solid tumours. \n \nUnder the terms of this agreement, ISA has granted Scancell an exclusive worldwide license to manufacture, develop and commercialise the AMPLIVANT®:Modi-1 conjugate therapy and will contribute know-how and expertise related to AMPLIVANT®. Clinical studies will be conducted by Scancell and are expected to commence in H1 2019. \n \nIn return, ISA will receive an upfront payment from Scancell and is entitled to milestone and royalty fees following achievement of certain criteria as defined in the agreement. Financial details were not disclosed.\n \nPrevious pre-clinical data demonstrated that conjugation of the Modi-1 peptides to AMPLIVANT® enhances anti-tumour immune responses 10-100 fold and resulted in highly efficient tumour eradication, including protection against tumour re-challenge.\n \nISA's AMPLIVANT® technology can be applied to any type of targeted immunotherapy, significantly enhancing its efficacy. It is based on a proprietary and synthetic small molecule TLR1/2 ligand with enhanced immunostimulatory activity that can be chemically coupled to the respective immunotherapeutic. AMPLIVANT® conjugates allow lower dosing with higher efficacy through better dendritic cell antigen processing and presentation, as well as enhanced T ...